title: [Changes in peripheral neuropathy and platinum concentrations in patients undergoing surgery following modified FOLFOX6 therapy].
abstract: BACKGROUND
  Gornet et al.(2002) reported that patients who received chemotherapy containing oxaliplatin for metastatic colorectal cancer experienced exacerbation of neurotoxicity after surgical resection and suggested that the possible mechanism behind exacerbation of neurotoxicity was perioperative transfer of accumulated platinum from the red blood cells into the plasma. However, no further reports about this issue have been published.
  
  
  METHODS
  We investigated changes of neurotoxicity after resection in three patients who received modified FOLFOX6 therapy prior to surgery. In addition, changes of the total plasma, ultrafiltrate, and erythrocyte platinum levels were determined by inductively coupled plasma mass spectrometry.
  
  
  RESULTS
  Exacerbation of neurotoxicity was not seen in any of the patients postoperatively. The platinum concentrations of all samples did not change significantly from before surgery to 4, 24, and 48 hours postoperatively.
  
  
  CONCLUSIONS
  Further assessment of patients is needed to draw a definite conclusion, but our preliminary data suggest that the risk of neurotoxicity exacerbation due to perioperative changes of the platinum pool is low.
authors.affiliation: Dept. of Digestive Tract Surgery, Saitama Medical Center, Saitama Medical University, Japan.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Motohiko
authors.initials: M
authors.lastname: Sano
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004906:Erythrocyte Count; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000097:blood* / Q000139:chemically induced*; D010984:Platinum / Q000097:blood* / Q000627:therapeutic use*
chemical_list: D009944:Organoplatinum Compounds; D010984:Platinum; D002955:Leucovorin; D005472:Fluorouracil